Vendor Intelligence Report: Simple Peptide

Executive summary

Across 29 Finnrick lab tests, Simple Peptide records 12 pass and 17 fail, an overall pass rate of 41%. The signal is uneven rather than uniformly bad: Tirzepatide is the relative bright spot, while CJC-1295 and BPC-157 are clear product-specific avoid signals. Retatrutide is fail-heavy and has a separate public batch-dispute record; ratings weaken under stricter grading assumptions.

Simple Peptide’s public accountability layer is thin. Investigators found no standalone Florida Simple Peptide entity; records tie the brand to Melex Technologies Inc. and a family-operated management structure not named on the site. The listed Delray Beach address is a commercial mail-drop, and the claimed move from imports to a U.S.-based manufacturer is not backed by public manufacturer identity, audits, or batch-transition detail.

The report also maps a wider Melex brand network. Alpha Omega Peptide links back through trademarks, shared address and infrastructure, privacy-policy fingerprints, and overlapping coupon promotion, changing how buyer reviews and nominally independent endorsements should be weighted. Code-heavy affiliates, brand-like social accounts, and two Palm Beach County disputes involving Melex and its former affiliate/business network add documented operational noise; the allegations remain unproven.

No public FDA warning letter was identified, and Simple Peptide’s COA page is a real documentation signal. The practical read is product-specific: do not generalize Tirzepatide’s stronger record to the whole storefront, and do not let coupon chatter offset weak lot-level history.

Inside the full report:

• Appendix A pass/fail rates, trajectories, and methodology-divergence charts for all 7 tested products
• Sunbiz records and court-complaint evidence tying the brand to Melex Technologies Inc.
• Alpha Omega Peptide sister-brand analysis using trademarks, certificates, address, and policy fingerprints
• Retatrutide Batch 20250415 dispute record and remediation screenshots
• Affiliate scan covering 18 promoter leads, disclosures, coupon hubs, and brand-like handles
• Palm Beach County litigation summary for Melex v. Baum and WoopBiz dissolution

Risk assessment

• Product-specific quality-control risk — high: High for CJC-1295, BPC-157, and Melanotan II: each recorded 0 passing Finnrick tests out of 3; Retatrutide is also fail-heavy at 3 pass / 4 fail.
• Quality-failure remediation risk — high: The Retatrutide Batch 20250415 dispute reported 86.87% label claim and screenshots alleging reimbursement was conditioned on changing a Trustpilot review, followed by subreddit removal.
• Corporate accountability and undisclosed sister-brand risk — medium: Simple Peptide is tied to Melex Technologies Inc.; the site does not name personnel, and Alpha Omega Peptide shares address, infrastructure, privacy-language, and affiliate promotion.
• Affiliate-promotion and brand-confusion risk — medium: The scan found 18 promoter leads and only 1 clear disclosure among 14 code/link promoters; brand-like X accounts and coupon hubs are not clearly separated from official channels.
• Internal-operations and litigation risk — medium: Melex litigation against Daniel and Heather Baum and a WoopBiz dissolution dispute allege trade-secret, customer, procedure, and formula issues, creating operational-volatility risk.